Clinical Trial Update: RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection [Phase 2]

View source ↗

Summary

This update covers the completion of a Phase 2 randomized trial evaluating Vapendavir in COPD patients with rhinovirus/enterovirus upper respiratory infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Lower Respiratory Infection
• Upper Respiratory Tract Infection

Drugs mentioned

• Vapendavir (vapendavir)

Snippet

Sponsor: Altesa Biosciences, Inc. | Conditions: COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection | Phase 2 | Status: COMPLETED